Dominari (NASDAQ:DOMH) Trading Down 1.4% – Here’s What Happened

Dominari Holdings Inc. (NASDAQ:DOMH) traded down 1.4% during trading on Monday . The stock traded as low as $2.77 and last traded at $2.79. Approximately 19,826 shares were traded during trading, a decline of 84% from the average daily volume of 121,804 shares. The stock had previously closed at $2.83.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Dominari in a research note on Monday, July 6th. Wall Street Zen raised Dominari from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Dominari Stock Performance

The firm has a market cap of $65.57 million, a price-to-earnings ratio of -0.72 and a beta of 0.84. The stock’s 50 day simple moving average is $3.21 and its 200-day simple moving average is $3.39.

Dominari (NASDAQ:DOMH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($2.11) EPS for the quarter, missing the consensus estimate of ($0.17) by ($1.94). The company had revenue of $35.81 million for the quarter, compared to analyst estimates of $35.80 million. Dominari had a negative return on equity of 206.20% and a negative net margin of 31.37%.

Dominari Dividend Announcement

The company also recently declared a special dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were given a dividend of $0.31 per share. The ex-dividend date of this dividend was Friday, May 15th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in Dominari by 2.9% in the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock valued at $361,000 after buying an additional 1,866 shares during the last quarter. PFG Investments LLC raised its position in Dominari by 36.3% during the 1st quarter. PFG Investments LLC now owns 14,475 shares of the company’s stock worth $47,000 after buying an additional 3,855 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in Dominari during the 4th quarter valued at approximately $50,000. Price T Rowe Associates Inc. MD acquired a new stake in Dominari during the 4th quarter valued at approximately $96,000. Finally, Oxford Asset Management LLP purchased a new stake in shares of Dominari in the 4th quarter valued at $120,000. 42.48% of the stock is owned by institutional investors and hedge funds.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.